vigil neuroscience is the world’s first microglia-focused therapeutics company. our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. we are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
Company profile
Ticker
VIGL
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
VIGL stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
S-8
Registration of securities for employees
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
26 Mar 24
8-K
Regulation FD Disclosure
11 Jan 24
8-K
Regulation FD Disclosure
16 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
Latest ownership filings
SC 13G/A
Artal International S.C.A.
29 Mar 24
4
Petra Kaufmann
20 Mar 24
3
Petra Kaufmann
20 Mar 24
4
Bruce Booth
5 Mar 24
4
Suzanne Louise Bruhn
5 Mar 24
4
Cheryl R Blanchard
5 Mar 24
4
Christopher Verni
1 Mar 24
4
Jennifer Lynn Ziolkowski
1 Mar 24
4
Ivana Magovcevic-Liebisch
1 Mar 24
4
David L. F. Gray
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.72 mm | 57.72 mm | 57.72 mm | 57.72 mm | 57.72 mm | 57.72 mm |
Cash burn (monthly) | 649.00 k | 12.26 mm | 7.44 mm | 6.99 mm | 5.77 mm | 6.00 mm |
Cash used (since last report) | 4.41 mm | 83.37 mm | 50.61 mm | 47.55 mm | 39.26 mm | 40.78 mm |
Cash remaining | 53.31 mm | -25.65 mm | 7.11 mm | 10.17 mm | 18.46 mm | 16.94 mm |
Runway (months of cash) | 82.1 | -2.1 | 1.0 | 1.5 | 3.2 | 2.8 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 54 |
Opened positions | 16 |
Closed positions | 7 |
Increased positions | 11 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 220.86 bn |
Total shares | 45.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Atlas Venture Life Science Advisors | 5.84 mm | $54.87 bn |
Atlas Venture Fund XII | 4.81 mm | $57.03 mm |
Northpond Ventures | 4.21 mm | $39.62 bn |
AMGN AMGEN | 3.21 mm | $38.03 mm |
Northpond Ventures | 2.83 mm | $26.56 mm |
Biotechnology Value Fund L P | 2.74 mm | $21.56 mm |
Artal International S.C.A. | 2.24 mm | $0.00 |
Citadel Advisors | 2.18 mm | $20.50 bn |
Deerfield Management | 2.05 mm | $19.29 bn |
Flynn James E | 2.05 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Petra Kaufmann | Stock Option Grant Common Stock | Grant | Acquire A | No | No | 3.14 | 330,000 | 1.04 mm | 330,000 |
1 Mar 24 | David L. F. Gray | Stock Option Grant Common Stock | Grant | Acquire A | No | No | 3.39 | 125,000 | 423.75 k | 125,000 |
1 Mar 24 | Magovcevic Ivana | Stock Option Grant Common Stock | Grant | Acquire A | No | No | 3.39 | 463,000 | 1.57 mm | 463,000 |
1 Mar 24 | Christopher Verni | Stock Option Grant Common Stock | Grant | Acquire A | No | No | 3.39 | 116,000 | 393.24 k | 116,000 |
News
JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target
19 Apr 24
JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target
18 Apr 24
Vigil Presents Key Findings From ILLUMINATE & IGNITE Studies In ALSP At The 2024 American Academy Of Neurology Annual Meeting
17 Apr 24
HC Wainwright & Co. Maintains Buy on Vigil Neuroscience, Maintains $24 Price Target
27 Mar 24
Vigil Neuroscience: Q4 Earnings Insights
26 Mar 24
Press releases
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
17 Apr 24
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
26 Mar 24
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
13 Mar 24
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
12 Mar 24
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
6 Mar 24